With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

The genetic concept of synthetic lethality has now been validated clinically through the
demonstrated efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of …

Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …

Clonal hematopoiesis of indeterminate potential (CHIP) describes a widespread expansion
of genetically variant hematopoietic cells that increases exponentially with age and is …

Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism,
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …

2-Hydroxyglutarate (2-HG) is structurally similar to α-ketoglutarate (α-KG), which is an
intermediate product of the tricarboxylic acid (TCA) cycle; it can be generated by reducing …

The members of the Poly (ADP‐ribose) polymerase (PARP) superfamily are involved in
several biological processes and, in particular, in the DNA damage response (DDR). The …

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the
immense heterogeneity of this disease, treating it using a “one size fits all” approach is …

Mutations in isocitrate dehydrogenase (IDH) genes occur in multiple cancer types, lead to
global changes in the epigenome, and drive tumorigenesis. Yet, effective strategies …